ArticleProceedings (Baylor University. Medical Center)2008
Hepatocellular carcinoma: management of an increasingly common problem.
Article in Proceedings (Baylor University. Medical Center), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: a validation set from China.Medicine · 2015Pooled it
- Preparation of cancer cell membrane-coated Gambogic acid-loaded pH-sensitive liposomes to enhance targeted anti-hepatocellular carcinoma effect.Drug delivery and translational research · 2026Article
- Palliative and supportive care in patients with hepatocellular carcinoma: a qualitative study on attitudes and perceptions of health professionals.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- A novel phosphodiesterase target as a therapeutic approach: inhibiting DEN-induced hepatocellular carcinoma progression.EXCLI journal · 2025Review
- Roles of organic anion transporting polypeptides in hepatocellular carcinoma.Frontiers in genetics · 2025Article
- Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.Frontiers in immunology · 2024Review
- Ligand-displaying-exosomes using RNA nanotechnology for targeted delivery of multi-specific drugs for liver cancer regression.Nanomedicine : nanotechnology, biology, and medicine · 2023Article
- Hepatocellular Carcinoma in Cirrhotic Versus Noncirrhotic Livers: Clinicomorphologic Findings and Prognostic Factors.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- Identification of DNA repair gene signature and potential molecular subtypes in hepatocellular carcinoma.Frontiers in oncology · 2023Article
- Elevated Serum Vinculin in Patients with HBV/HCV-Associated Liver Cirrhosis and Hepatocellular Carcinoma: A Pilot Study.Biologics : targets & therapy · 2023Article
- Magnetic Resonance Imaging Predictors of Hepatocellular Carcinoma Progression and Dropout in Patients in Liver Transplantation Waiting List.Transplantation direct · 2022Article
- Development and validation of personalised risk prediction models for early detection and diagnosis of primary liver cancer among the English primary care population using the QResearch® database: research protocol and statistical analysis plan.Diagnostic and prognostic research · 2022Article
- Identification of crucial lncRNAs and mRNAs in liver regeneration after portal vein ligation through weighted gene correlation network analysis.BMC genomics · 2022Article
- Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.Liver cancer · 2022Review
- Acute-phase serum amyloid A for early detection of hepatocellular carcinoma in cirrhotic patients with low AFP level.Scientific reports · 2022Article
- African Immigrants in New York City with Hepatitis B-Related Hepatocellular Carcinoma Demonstrate High Morbidity and Mortality.Journal of immigrant and minority health · 2022Article
- Regulatory mechanisms and potential medical applications of HNF1A-AS1 in cancers.American journal of translational research · 2022Review
- Prediction of risk-associated genes and high-risk liver cancer patients from their mutation profile: benchmarking of mutation calling techniques.Biology methods & protocols · 2022Article
- Mulberry fruit polysaccharides alleviate diethylnitrosamine/phenobarbital-induced hepatocarcinogenesis in vivo: the roles of cell apoptosis and inflammation.Bioengineered · 2021Article
- Proteomic Research on the Antitumor Properties of Medicinal Mushrooms.Molecules (Basel, Switzerland) · 2021Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a common cancer that typically occurs in the setting of cirrhosis and chronic hepatitis virus infections. Hepatitis B and C account for approximately 80% of cases worldwide. HCC is currently the fifth most common malignancy in men and the eighth in women worldwide; its incidence is increasing dramatically in many parts of the world. Recognition of those at risk and early diagnosis by surveillance with imaging, with or without serologic testing, are extremely important. Many highly effective and even curative therapies are now available and include resection, liver transplantation, and local ablation. Appropriate application of these interventions offers hope of prolonged survival to many patients with this otherwise lethal complication of liver disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.